Why the study?
Does ROCK pathway inhibition prevent or treat atrial fibrillation?
Does ROCK pathway inhibition prevent or treat atrial fibrillation?
The RhoA/ROCK pathway plays a key role in atrial fibrotic remodeling and calcium dysregulation, making it a potential therapeutic target for atrial fibrillation.
Among the complex mechanisms of AF pathogenesis, intracellular calcium overload and oxidative stress play a major role, both triggered by inflammatory processes. The additional basic event taking place in AF is atrial fibrotic remodeling, again triggered by oxidative stress, which is determined by connexins rearrangement and differentiation of fibroblasts into active collagensecreting myofibroblasts. RhoA/ROCK system is the final pathway of a wide spectrum of molecular effectors such as Angiotensin II, platelet-derived growth factor, connective tissue growth factor and transforming growth factor β, that overall determine calcium dysregulation and pro-fibrotic remodeling. Both in experimental and clinical studies, RhoA/ROCK activation has been linked to superoxide ion production, fibrotic remodeling and connexins rearrangement, with important consequences for AF pathogenesis. ROCK pathway inhibition may therefore be a therapeutic or preventive target for special AF subgroups of patients.
No takes yet. Share an insight, caveat, or question.
Proietti et al. (2022) conducted a review in Atrial Fibrillation. ROCK pathway inhibition was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: